Agios Pharmaceuticals vs Akebia Therapeutics
AGIO and AKBA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGIO and AKBA compare
Agios Pharmaceuticals is the larger company, worth 14 times as much as Akebia Therapeutics ($1.9B against $131M).
Agios Pharmaceuticals grew revenue faster over the last twelve months (214% versus −12.4% for Akebia Therapeutics).
Akebia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −22.6% compared with −265% at Agios Pharmaceuticals.
Agios Pharmaceuticals scores higher on the StockData Score (13 against 4 for Akebia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGIO | AKBA |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $131M |
| Share price | $31.59 | $0.474 |
| Change, 1 year | −27.6% | −74.4% |
| Change, 5 years | −17.3% | −82.9% |
| Beta (5Y) | 1.41 | 1.10 |
| Employees | 539 | 194 |
| StockData Score | ||
| Total score | 13 (better) | 4 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 13.4× | 0.7× (better) |
| P/B | 1.9× (better) | 6.5× |
| P/FCF | – | 9.5× |
| FCF yield | −17.8% | 10.5% (better) |
| Fair value | $32.10 | – |
| Margin of safety | 1.6% | – |
| Growth | ||
| Revenue growth (TTM) | 214% (better) | −12.4% |
| Revenue growth, 5Y average | – | −4.3% |
| Profitability | ||
| Gross margin | 93.8% (better) | 78.9% |
| Operating margin | −298% | −15.7% (better) |
| Net margin | −265% | −22.6% (better) |
| FCF margin | −239% | 7.0% (better) |
| Return on equity | −32.9% (better) | −144% |
| Return on invested capital | −1169% | – |
| Financial health | ||
| Debt / equity | 0.00 | 2.47 (better) |
| Current ratio | 9.69 (better) | 1.36 |
| Altman Z-score | 11.86 (better) | −6.30 |
| Piotroski F-score | 1 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 111% | 39.7% |
| Held by insiders | 1.1% | 2.9% |
| Insider net buying, 12 months | −$4.9M | −$876K (better) |
| Short interest, % of float | 11.1% | 10.1% |
Go deeper
- AGIO stock overview
- AGIO income statement
- AGIO valuation and score
- AKBA stock overview
- AKBA income statement
- AKBA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.